1.Hansen's Disease relapse: A 5-year multi-center, retrospective study on epidemiological and clinical patterns in selected tertiary government hospitals in the Philippines from November 2016 to October 2021.
Kelsie Kirsty SANTOS ; Vilma C. RAMILO ; Frederica Veronica MARQUEZ-PROTACIO ; Czarina Katherine DELA TORRE ; Ricky H. HIPOLITO ; Bianca Victoria C. PENA ; Dee Jay B. ARCEGA
Journal of the Philippine Medical Association 2025;103(2):43-53
BACKGROUND
Efforts to control Hansen's d isease have progressed through multidrug therapy implementation. However, documented cases of relapse present challenges to its effective management and eradication. Understanding the contributing factors to relapse is crucial for optimizing treatment strategies and achieving better outcomes against Hansen's Disease.
OBJECTIVETo determine the epidemiological profile and clinical patterns of patients diagnosed with Hansen's Disease Relapse in selected Tertiary Government Hospitals in the Philippines from November 2016 to October 2021.
METHODOLOGYThis was a multi-center, retrospective study involving a five-year chart review method. Charts of all Hansen's Disease Relapse patients were obtained from participating institutions with necessary approvals. Data collection followed approved forms, and patient profiles were analyzed using descriptive statistics. Pre- and post- relapse profiles were compared using T-tests, Wilcoxon tests, and Fisher's Exact Test. Relapse time across subgroups were assessed using Kruskal-Wallis and Mann-Whitney U tests.
RESULTSA total of 60 relapse cases were included in the study. Majority were single, unemployed males aged 26-35, with low household screening. The Bacillary Index significantly decreased post- relapse. Documented comorbidities included G6PD deficiency before treatment and lepra reactions during MDT. Patients on 12-month MDT regimens had higher relapse time than those on 24-month regimens.
CONCLUSIONThis study underscores the influence of socioeconomic, gender, and age-related factors on relapse. It emphasizes the imperative for enhanced public health measures in accordance with the WHO Global Leprosy Strategy and the importance of considering clinical factors while advocating for continuous improvements in leprosy management protocols.
Human ; Multiple Chronic Conditions